All In Biotech

NDA 020415 · Organon

Remeron

Mirtazapine · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Jul 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Jun 14, 1996

Approved uses

2

Original approval plus efficacy supplements

Registered trials

127

25 Phase 3, 7 recruiting

FAERS reports

93,069

77,961 serious, 14,287 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] . REMERON/REMERONSolTab is not approved for use in pediatric patients [see Use in Specific Populations (8.4) ]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. REMERON/REMERONSolTab is not approved for use in pediatric patients. ( 5.1 , 8.4 )

What it is approved for

From the label in effect Aug 6, 2025.

REMERON/REMERONSolTab are indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies (14) ] . REMERON/REMERONSolTab is indicated for the treatment of major depressive disorder (MDD) in adults. ( 1 )

Mechanism: The mechanism of action of mirtazapine for the treatment of major depressive disorder, is unclear. However, its efficacy could be mediated through its activity as an antagonist at central presynaptic α 2 -adrenergic inhibitory autoreceptors and heteroreceptors and enhancing central noradrenergic and serotonergic activity.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • REMERON · MIRTAZAPINE 30MG · TABLET, ORAL · Prescription · TE AB
  • REMERON · MIRTAZAPINE 45MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • REMERON · MIRTAZAPINE 15MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Mirtazapine" as an intervention, any sponsor and status, largest first.

All 127 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea5,124
  • fatigue5,006
  • drug ineffective4,903
  • fall4,248
  • diarrhoea4,175
  • off label use4,082
  • toxicity to various agents3,985
  • dizziness3,670
  • anxiety3,652
  • dyspnoea3,602
  • death3,521
  • drug interaction3,468

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,058
20051,207
20061,307
20071,300
20081,305
20091,892
20102,234
20112,590
20122,748
20132,527
20143,087
20154,008
20164,596
20175,114
20186,608
20197,303
20207,212
20216,131
20226,330
20236,409
20246,273
20256,720
20265,107

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Remeron (Mirtazapine)

2024 spending

$732K

Beneficiaries

465

2,169 claims

Per beneficiary

$1,573

$5.76 per unit

View as table
YearSpending
2020$0
2021$136,560
2022$756,226
2023$790,626
2024$731,560

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 541 on PubMed

Sponsor: Organon

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.